Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.66 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10679645 | 0.87 | RAB9A (0.58) | RAB9AMAPTSMN1; SMN2HPGDNPSR1 | |
| SCHEMBL2147069 | 0.87 | RAB9A (0.69) | RAB9AMAPTSMN1; SMN2HPGDNPSR1 | |
| SCHEMBL10673602 | 0.85 | RAB9A (0.62) | RAB9AMAPTSMN1; SMN2HPGDNPSR1 | |
| SCHEMBL4235445 | 0.84 | RAB9A (0.86) | RAB9AMAPTSMN1; SMN2HPGDNPSR1 | |
| SCHEMBL17273630 | 0.83 | RAB9A (0.60) | RAB9AMAPTSMN1; SMN2HPGDNPSR1 | |
| SCHEMBL1999435 | 0.83 | RAB9A (0.90) | RAB9AMAPTSMN1; SMN2HPGDNPSR1 | |
| SCHEMBL10675380 | 0.82 | RAB9A (0.59) | RAB9AMAPTSMN1; SMN2HPGDNPSR1 | |
| SCHEMBL24658769 | 0.82 | RAB9A (0.77) | RAB9AMAPTSMN1; SMN2HPGDNPSR1 | |
| SCHEMBL11996369 | 0.81 | RAB9A (0.87) | RAB9AMAPTSMN1; SMN2HPGDNPSR1 | |
| SCHEMBL8554591 | 0.81 | RAB9A (0.87) | RAB9AMAPTSMN1; SMN2HPGDNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260063640-A1 | Reagents for Directed Biomarker Signal Amplification | SIRIGEN II LTD (GB) | 2026-03-05 | — | — | US | disclosed |
| US-20250362301-A1 | Fluorescent Methods and Materials for Directed Biomarker Signal Amplification | SIRIGEN II LTD (GB) | 2025-11-27 | — | — | US | disclosed |
| US-12366578-B2 | Fluorescent methods and materials for directed biomarker signal amplification | SIRIGEN II LIMITED (GB) | 2025-07-22 | — | — | US | disclosed |
| US-12366577-B2 | Fluorescent methods and materials for directed biomarker signal amplification | SIRIGEN II LIMITED (GB) | 2025-07-22 | — | — | US | disclosed |
| US-12345713-B2 | Reagents for directed biomarker signal amplification | SIRIGEN II LIMITED (GB) | 2025-07-01 | — | — | US | disclosed |
| US-12253525-B2 | Reagents for directed biomarker signal amplification | SIRIGEN II LIMITED (GB) | 2025-03-18 | — | — | US | disclosed |
| US-12241898-B2 | Reagents for directed biomarker signal amplification | SIRIGEN II LIMITED (GB) | 2025-03-04 | — | — | US | disclosed |
| US-12235274-B2 | Reagents for directed biomarker signal amplification | SIRIGEN II LIMITED (GB) | 2025-02-25 | — | — | US | disclosed |
| US-12153050-B2 | Reagents for directed biomarker signal amplification | SIRIGEN II LIMITED (GB) | 2024-11-26 | — | — | US | disclosed |
| US-12111321-B2 | Reagents for directed biomarker signal amplification | SIRIGEN II LIMITED (GB) | 2024-10-08 | — | — | US | disclosed |
| US-20110256550-A1 | Novel reagents for directed biomarker signal amplification | SIRIGEN, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| WO-2011091086-A1 | NOVEL REAGENTS FOR DIRECTED BIOMARKER SIGNAL AMPLIFICATION | SIRIGEN INC. (US) | 2011-07-28 | — | — | WO | disclosed |
| WO-2011091086-A1 | NOVEL REAGENTS FOR DIRECTED BIOMARKER SIGNAL AMPLIFICATION | SIRIGEN INC. (US) | 2011-07-28 | — | — | WO | disclosed |
| WO-2010151807-A1 | SIGNAL AMPLIFIED BIOLOGICAL DETECTION WITH CONJUGATED POLYMERS | SIRIGEN, INC. (US) | 2010-12-29 | — | — | WO | disclosed |
| EP-2164988-A2 | FLUORESCENT METHODS AND MATERIALS FOR DIRECTED BIOMARKER SIGNAL AMPLIFICATION | Sirigen Inc. (US) | 2010-03-24 | — | — | EP | disclosed |
| US-20080293164-A1 | Fluorescent Methods and Materials for Directed Biomarker Signal Amplification | SIRIGEN INC. | 2008-11-27 | — | — | US | disclosed |
| US-20080293164-A1 | Fluorescent Methods and Materials for Directed Biomarker Signal Amplification | SIRIGEN INC. | 2008-11-27 | — | — | US | disclosed |
| US-20080293164-A1 | Fluorescent Methods and Materials for Directed Biomarker Signal Amplification | SIRIGEN INC. | 2008-11-27 | — | — | US | disclosed |
| WO-2008100344-A2 | FLUORESCENT METHODS AND MATERIALS FOR DIRECTED BIOMARKER SIGNAL AMPLIFICATION | SIRIGEN INC. (US) | 2008-08-21 | — | — | WO | disclosed |
| WO-2008100344-A2 | FLUORESCENT METHODS AND MATERIALS FOR DIRECTED BIOMARKER SIGNAL AMPLIFICATION | SIRIGEN INC. (US) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12253525-B2 | Reagents for directed biomarker signal amplification | RNGTT, CAPG, CA14 | RAB9A 3811/4885MAPT 3033/4885SMN1; SMN2 3540/4885 |
| US-12235274-B2 | Reagents for directed biomarker signal amplification | RNGTT, CAPG, CA14 | RAB9A 3811/4885MAPT 3033/4885SMN1; SMN2 3540/4885 |
| US-12345713-B2 | Reagents for directed biomarker signal amplification | RNGTT, CAPG, CA14 | RAB9A 3811/4885MAPT 3033/4885SMN1; SMN2 3540/4885 |
| US-12111321-B2 | Reagents for directed biomarker signal amplification | RNGTT, CAPG, CA14 | RAB9A 3811/4885MAPT 3033/4885SMN1; SMN2 3540/4885 |
| US-12241898-B2 | Reagents for directed biomarker signal amplification | RNGTT, CAPG, CA14 | RAB9A 3811/4885MAPT 3033/4885SMN1; SMN2 3540/4885 |
| US-20260063640-A1 | Reagents for Directed Biomarker Signal Amplification | RNGTT, RNMT, DNMT3L | RAB9A 4250/4885MAPT 1844/4885SMN1; SMN2 856/4885 |
| US-20110256550-A1 | Novel reagents for directed biomarker signal amplification | RNGTT, CAPG, CD2BP2 | RAB9A 3757/4885MAPT 3230/4885SMN1; SMN2 3493/4885 |
| US-12153050-B2 | Reagents for directed biomarker signal amplification | RNGTT, CAPG, CA14 | RAB9A 3811/4885MAPT 3033/4885SMN1; SMN2 3540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.